coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Tame Valley PCN, Stockport (LAD) · Health Inequalities Profile

    PCN U99971 · NHS Greater Manchester Integrated Care Board · 8 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    59,554

    Registered population

    62.6% aged 18–64

    16.8%

    Aged 65+

    ICB 14.9% · England 17.9%

    43.3%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~22,111

    Core20 residents (est.)

    Resident basis; registered basis ~25,697 · see page 3

    9,666

    Hypertension register

    +5.27% in 3 yrs · England +5.60%

    650

    SMI register

    19.5% of Stockport (LAD)'s

    1,919

    COPD register

    Reviews -9.77% in 3 yrs

    Forecast to 2030

    10,986

    Hypertension patients, 2030

    +1,320 on today

    75.4%

    QRISK ≥20% on statins, 2030

    +2.46pp over 3 yrs

    4.4%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    61.2%
    Asthma annual reviews fall behind national trends.

    Coverage is 61.2% (England 65.7%) after a -9.1% three-year change (England +4.4%), leaving about 1,500 unreviewed patients, which could reflect recall limits.

    86.7%
    Pre-school booster coverage trails the 95.0% target.

    Age-5 4-in-1 booster uptake is 86.7% (8.3 pp below the 95.0% target) and MMR dose 2 is 92.1%, which may indicate recall gaps.

    70.0%
    Hypertension blood pressure control exceeds national averages.

    Control reaches 70.0% in patients under 80 (England 67.8%, ICB 68.6%) and 84.5% in those aged 80+ (England 81.2%, Stockport 83.8%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Older adults make up 16.8% of registered patients, below Stockport's 19.7% comparator

    Across 59,554 registered patients, 16.8% (10,009 patients) are aged 65+, below Stockport (19.7%), above NHS Greater Manchester ICB (14.9%), and below England (17.9%). Children aged 0–17 make up 20.6% (12,240 patients; Stockport 19.7%, ICB 21.8%, England 19.6%). Census estimates record Gypsy or Irish Traveller residents at 0.1% and Roma at 0.1%. Catchment care homes total 14 with 562 beds, including 6 associated with Alvanley Family Practice and 5 with Brinnington Surgery. List size is projected to grow 1.2% to 2030 (Stockport 1.1%, ICB 1.6%, England 2.3%) under an unverified methodology.

    Age profile

    0–1720.6%
    18–6462.6%
    65+16.8%

    65+: ICB 14.9%, England 17.9%

    Older people · falls rows are Stockport (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Stockport LA)2,0722,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)84.6%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)56.1%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Stockport LA)9191,0219552024/25
    Falls deaths, all ages, per 100,000 (Stockport LA)23.718.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 patients make up 43.3% of the PCN list, above Stockport and England

    Core20 patients make up 43.3% of the PCN list, above Stockport (16.1%), NHS Greater Manchester Integrated Care Board (40.7%), and England (21.0%). Across captured practices, Woodley Village Surgery records a Core20 cohort share of 15.0%. Brinnington Surgery records a Core20 cohort share of 92.4% (8,712 estimated patients). Heaton Norris Medical Practice records a Core20 cohort share of 51.0% (5,397 estimated patients). Family Surgery records a Core20 cohort share of 29.1% (3,305 estimated patients). Resident Core20 estimates (22,111) and practice registered estimates rest on different bases.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Brinnington92.4% · 8,712 patients
    Vernon Park51.3% · 1,771 patients
    Heaton Norris51.0% · 5,397 patients
    Park View32.6% · 3,285 patients
    Family29.1% · 3,305 patients
    Bredbury24.9% · 1,575 patients
    Alvanley22.6% · 1,203 patients
    Woodley Village15.0% · 449 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    650

    SMI register

    1.09% recorded prevalence

    392

    Learning disability register

    0.66% recorded prevalence

    14

    Care homes, 562 beds

    In the PCN catchment

    9.5%

    Provide unpaid care

    Stockport (LAD), Census 2021

    Recorded severe mental illness includes 650 patients (1.1%; Stockport 1.0%, ICB 1.1%, England 1.0%) and learning disabilities 392 patients (0.7%; Stockport 0.6%, ICB 0.6%, England 0.6%). Borough rough sleeping was 48 in 2025 and unpaid care was 9.5% in 2021; borough-level figures capture wider local authority context and do not establish PCN list counts.

    Severe mental illness: physical health checks

    SMI prevalence is 1.1% (650 patients). Recorded checks reached 83.9% for blood pressure (Stockport 85.0%, England 83.4%) and 82.0% for BMI (Stockport 84.0%, England 82.1%), meaning routine monitoring trails borough levels while unrecorded elements cannot imply completed full checks.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    9,666

    Hypertension register

    +5.27%

    Register growth, 3 yrs

    Stockport (LAD) +4.99% · England +5.60%

    +2.93pp

    BP control, under 80

    ≤140/90 · +3.17pp aged 80+

    +1,320

    More patients by 2030

    Forecast 10,986 (18.03%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 16.3% (9,666 patients), above England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%), and in line with Stockport (16.2%). Recent blood pressure checks reach 90.3% (England 90.0%, Stockport 91.2%). Blood pressure control exceeds national averages: 70.0% aged under 80 achieve <= 140/90 mmHg (England 67.8%, Stockport 70.8%) after a +4.4% three-year rise (England +3.2%), and 84.5% aged 80+ are controlled (England 81.2%). Conversely, annual reviews across 796 heart failure patients fell 9.6% over 2023 to 2025 (England +8.7%) to 73.7%, trailing England (78.5%) and Stockport (79.3%). While hypertension control outperforms England, trailing heart failure reviews could reflect recall capacity limits, testable by auditing appointments.

    Lipids and statins

    Lipid-lowering therapy reaches 70.2% for patients with QRISK >= 20%, exceeding England (63.6%), Stockport (64.8%), and NHS Greater Manchester Integrated Care Board (67.0%). Treatment in chronic kidney disease is 77.7% (England 70.3%). Higher therapy coverage than England is consistent with effective prevention, indicating the PCN should prioritise sustaining treatment pathways across all practices.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026130,439£1.70£1.94£1.86£221,746
    Cardiovascular (all), 2025178,585£3.06£3.15£3.33£546,470

    In 2026, the PCN prescribed 130,439 lipid-regulating drug items at £1.70 per item, below England (£1.86), NHS Greater Manchester Integrated Care Board (£1.94), and Stockport (£1.99), spending £20,870 less than at England's unit cost.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −9.14%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −0.14%

    Asthma prevalence, PCN 3-yr % change

    COPD prevalence is 3.2% (1,919 patients; Stockport 2.1%), after register growth of +10.1% over 2023 to 2025 (England +2.6%). Over that period, COPD reviews fell 9.8% (England +2.8%) to 68.4% (Stockport 76.4%, England 76.4%). Asthma reviews fell 9.1% (England +4.4%) to 61.2% (Stockport 63.4%, England 65.7%), leaving about 1,500 of 3,935 patients unreviewed. Youth asthma prescribing reached 2,177 per 1,000 aged 5-19 (Stockport 1,720, England 1,488). Falling review coverage could reflect appointment recall bottlenecks, testable by auditing appointments.

    Cancer register and children's immunisation

    The cancer register records 2,200 patients (3.7%; England 3.8%, Stockport 4.4%). In Q1 2025/26 childhood immunisations, age-5 MMR dose 1 achieved 97.0%, while dose 2 reached 92.1% (4.9 pp lower; 2.9 pp below the 95.0% target). The 4-in-1 booster reached 86.7% (8.3 pp below the 95.0% target; England 80.9%).

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months92.8%

    England 91.0%

    6-in-1 complete primary course at 24 months94.6%

    England 92.2%

    MMR dose 1 at 24 months92.6%

    England 88.3%

    MMR dose 2 at age 592.1%

    England 82.8%

    4-in-1 pre-school booster at age 586.7%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    Across NHS Greater Manchester ICB in 2022, 55.6% of staged cancers were diagnosed at stage 1 or 2 (England 55.3%), showing a distance of -19.4 pp to the 75.0% national ambition by 2028, with 70.8% known staging; reaching 75.0% would require about 2,270 additional early-stage diagnoses annually across the ICB. Within Tame Valley PCN, recorded cancer prevalence is 3.7% (2,200 patients). Breast screening coverage is 63.2% (Stockport 72.6%, England 69.9%). Cervical screening among women aged 25 to 49 is 73.0% (Stockport 75.9%), with a 3-year percentage change of -1.9%. These ICB figures reflect wider system staging rather than PCN performance. Lower breast screening coverage compared to England and Stockport, alongside.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    For Stockport NHS Foundation Trust, 62-day referral to treatment performance is 74.6666%, trailing the 85.0% operational standard by 10.3 pp, while NHS Greater Manchester Integrated Care Board stands at 75.7262% (9.3 pp below standard). Faster diagnosis standards are met: Stockport NHS Foundation Trust achieved 83.2086% on the 28-day standard (8.2 pp above the 75.0% standard; ICB 79.5261%), and 97.3913% on the 31-day combined treatment standard (1.4 pp above the 96.0% standard; ICB 96.4937%). Hospital wait standards describe acute trust pathways rather than PCN performance. Diagnostic bottlenecks at trust level mean primary care must maintain rapid referral quality for suspected cancers.

    Pathways within standard (%)StockportManchesterTameside and Glossop Integrated CareGreater Manchester ICBEngland
    28-day faster diagnosis (75%)83.2180.0682.4879.5379.32
    31-day treatment (96%)97.3992.5496.2596.4992.50
    62-day referral to treatment (85%)74.6772.8576.7775.7371.16
    Diagnostic waits over 6 weeks (%)StockportManchesterTameside and Glossop Integrated CareEngland
    MRI1.4111.680.0021.40
    CT2.9314.660.189.92
    Echocardiography17.464.910.0028.48
    Colonoscopy5.534.511.5130.83
    Gastroscopy5.3129.355.4529.02
    All 15 DM01 tests14.088.980.8023.14
    Community services activityStockport residentsGreater Manchester ICB
    Care contacts57,085573,310
    Referrals10,69094,470
    Patients with a contact16,950183,535

    Community services (residents of Stockport), Jun 2026 (provisional). Community service activity recorded across Stockport borough shows that adults aged 65 and over account for 60.6% of all resident contacts, representing 34,585 of the 57,085 total community contacts. These borough-level figures capture resident community service activity rather than individual PCN practice activity. High community contact concentration among older residents highlights the necessity of close coordination between PCN primary care teams and community services.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Phone access spans 51.7 percentage points across practices despite high overall QOF achievement

    Overall 2025/26 QOF achievement ranges from 90.6% at Brinnington Surgery to 98.2% at Vernon Park Surgery. However, vaccination and immunisation domain achievement spans 61.3 pp, from 24.9% at Alvanley Family Practice to 86.2% at Vernon Park Surgery (England 55.2%). High overall achievement may mask substantial inter-practice variation in routine immunisation delivery.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Bredbury11724.994.9%83.2%93.8%
    Vernon Park10651.396.7%73.7%92.3%
    Heaton Norris10851.064.7%70.5%87.4%
    Brinnington10492.493.1%80.0%86.3%
    Family Surgery10829.144.9%49.4%81.6%
    Alvanley9522.671.7%69.1%81.5%
    Woodley Village10515.092.9%67.4%79.5%
    Park View10532.670.7%76.1%75.5%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNStockport (LAD)AssetPCNStockport (LAD)
    Care homes (catchment)14 (562 beds)n/aSchools (catchment)86n/a
    Children's centres12Places of worship38135
    Libraries512Food banks (VCS)n/a1
    Homelessness support (VCS)1no dataPrimary schools (LA maintained)1261
    Primary academies1323Special schoolsn/a4

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review and prescribing recall

    Asthma review coverage is 61.2% (Stockport 63.4%, England 65.7%) after a -9.1% change over 2023 to 2025 (England +4.4%), leaving 1,525 (about 1,500) of 3,935 patients unreviewed alongside 2,177 youth asthma items per 1,000 (England 1,488). Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Pre-school booster and MMR2 catch-up

    In Q1 2025/26 across 165 five-year-olds, 4-in-1 booster coverage is 86.7% (below the 95.0% target by 8.3 pp; England 80.9%) and MMR dose 2 is 92.1% (4.9 pp below MMR dose 1 at 97.0%). Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Option 3

    Combined COPD and heart failure recall

    Over 2023 to 2025, COPD reviews across 1,919 patients (3.2%) fell 9.8% (England +2.8%) to 68.4% (England and Stockport 76.4%), and heart failure reviews across 796 patients (1.3%) fell 9.6% (England +8.7%) to 73.7% (England 78.5%). Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Care home primary care alignment (p2)Count of Care Homes in PCN catchmentFit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026PCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check recall audit (p4)SMI register with a BMI recorded in the last 12 monthsMHIS · From Harm to HopePCN
    Heart failure annual review recall (p5)Heart failure register—PCN
    Pre-school booster and MMR recall (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Telephony and triage capacity review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Structured asthma review and prescribing recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 PopulationCore20PLUS5 respiratoryPCN
    Option 2 · Pre-school booster and MMR2 catch-up (p12)4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Option 3 · Combined COPD and heart failure recall (p12)COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 monthsCore20PLUS5 approach · Tobacco and Vapes BillPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15